Please sign in to follow a disease.

Relapsed or refractory NK/T-cell lymphoma

Clinical trials for Relapsed or refractory NK/T-cell lymphoma explained in plain language.

Never miss a new study

Get alerted when new Relapsed or refractory NK/T-cell lymphoma trials appear

Sign up with your email to follow new studies for Relapsed or refractory NK/T-cell lymphoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1 Not yet recruiting 1

New combo attack on rare blood cancer shows promise in early trial

Disease control Recruiting now

This study tests two drugs, tislelizumab and zeprumetostat, together in people with a rare type of lymphoma that has come back or not responded to treatment. About 107 adults will take part to see if the combination is safe and shrinks tumors. The goal is to control the cancer, n…

Matched conditions: RELAPSED OR REFRACTORY NK/T-CELL LYMPHOMA

Phase 1/2 • Sponsor: Rong Tao • Aim: Disease control

Last updated Jun 27, 2026 14:00 UTC

Relapsed or refractory NK/T-cell lymphoma

Get alerted when new Relapsed or refractory NK/T-cell lymphoma trials appear

New combo attack on rare blood cancer shows promise in early trial